Management of Hypertension Using Olmesartan Alone or in Combination
MetadataShow full item record
CitationZhang, Xiaoshen, Han Zhang, Yuxia Ma, Wenliang Che, and Michael R. Hamblin. 2017. “Management of Hypertension Using Olmesartan Alone or in Combination.” Cardiology and Therapy 6 (1): 13-32. doi:10.1007/s40119-017-0087-5. http://dx.doi.org/10.1007/s40119-017-0087-5.
AbstractHypertension is one of the most significant and consistent risk factors for many cardiovascular diseases. The global prevalence of hypertension has dramatically increased over recent years. Life-style and genetic factors are generally considered to be primarily responsible for the incidence of hypertension. Concerning the high morbidity rate, setting up an updated standard for hypertensive patients becomes indispensable. According to the widely accepted standard treatments for hypertension, these four basic principles should be taken into account: low dosage; medication should provide long term-control; combination therapies are becoming common; personalized treatments are a newer approach. In most patients with hypertension, adequate control of BP can be achieved with combined therapy. Therefore, antihypertensive agents with complementary mechanisms are now recommended. In this review, we focus on the pharmacology, antihypertensive efficacy, and adverse events (AEs) of olmesartan medoxomil, either alone or in combination with other antihypertensive medications. In conclusion, olmesartan medoxomil, is an angiotensin II receptor blocker with an excellent efficacy in the reduction and stabilization of blood pressure. When combined with calcium channel blockers (CCBs) and diuretics, olmesartan medoxomil has a better effect on controlling BP and reducing AEs in patients.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:33439351
- HMS Scholarly Articles